Filgrastim is a granulocyte colony-stimulating factor (G-CSF) that stimulates the production of neutrophils, and is used to prevent or treat febrile neutropenia in patients undergoing chemotherapy. Hypersensitivity reactions (HSRs) to G-CSF formulations, such as filgrastim, pegfilgrastim and biosimilars are rare, and few reports exist regarding desensitization protocols, particularly in the pediatric population. In this brief report, we describe successful desensitization and subsequent use of G-CSF (biosimilar product Nivestym®) in an adolescent with Hodgkin lymphoma who experienced anaphylaxis after her first dose.